Public company intelligence preview
GREENWICH LIFESCIENCES INC
9 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $2.7M average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 50 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Greenwich Lifesciences Inc. (NASDAQ: GLSI) is a clinical-stage biotechnology company in the Healthcare sector and Biotechnology industry focused on GLSI-100, a breast cancer recurrence immunotherapy for HER2/neu-positive patients. Its lead asset is the Phase III Flamingo-01 trial, which is being expanded into Europe with plans for up to 150 global sites, underscoring that the company is still in a development-heavy, pre-revenue stage. The business is centered on clinical execution rather than product sales, with future commercialization expected only after regulatory success. It relies heavily on outsourced manufacturing, third-party partners, and key licensed intellectual property from the Henry M. Jackson Foundation.
Executive Compensation Practices
For a clinical-stage biotech like GLSI, executive compensation is typically tied more to development milestones, financing execution, and clinical progress than to revenue or earnings growth. The filing summaries show that stock-based compensation is a meaningful part of pay, with option vesting contributing materially to both 2024 and 2025 expense increases, which suggests equity awards are an important retention and incentive tool. In this industry, compensation structures often emphasize long-term equity grants, especially when cash is limited and the company is funding a single high-stakes Phase III program. Because the company is pre-revenue and burning cash, compensation decisions may be sensitive to capital-raising needs, trial milestones, and dilution concerns.
Insider Trading Considerations
Insider trading patterns in a company like GLSI may be influenced more by clinical readouts, trial enrollment updates, financing events, and regulatory milestones than by traditional operating results. The company’s small size, limited cash balance, and repeated reliance on ATM sales and other equity financing can create periods when insiders are especially restricted from trading or may avoid transactions around financing windows. For investors, insider purchases could be viewed as a stronger signal of confidence in Flamingo-01 progress or funding prospects than in mature companies, while insider sales may reflect liquidity needs, option exercises, or diversification rather than negative fundamentals. Because the company operates in the Biotechnology industry, trading activity can also be highly event-driven around FDA interactions, trial expansions, and public data releases.
Unlock the full GLSI insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.